Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
17 oct. 2024 07h01 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
14 oct. 2024 16h30 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 02h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
05 sept. 2024 17h34 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE
|
Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
09 mai 2024 16h30 HE
|
Travere Therapeutics, Inc.
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
30 avr. 2024 14h40 HE
|
Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 avr. 2024 07h05 HE
|
Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03 avr. 2024 16h30 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics to present abstracts at World Congress of Nephrology and American Nephrology Nurses Association on Rare Kidney Disease